At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 40 enrolled
Drug / intervention
vildagliptin and metformin (combination) +2 moredrug
Likely dose
vildagliptin and metformin (combination) 50mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Glycemic Excursions in Type 2 Diabetic Patients Treated With Vildagliptin and Metformin (GalvusMet) Versus Glimepiride and Metformin
In Brief
A Phase 4 clinical trial evaluating vildagliptin and metformin (combination), glimepiride, and 1 other intervention for Type 2 Diabetes and Hypoglycemia. Completed, enrolled 40 participants across 8 sites.
Detailed Summary
The purpose of this study was to compare the effect of a fixed dose combination of vildagliptin plus metformin versus combination therapy of glimepiride plus metformin in glycemic variability in patients with type 2 diabetes who have not achieved adequate control of their disease prior to treatment with metformin monotherapy in optimal doses.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes, Hypoglycemia
CountriesColombia
Collaborators--
Timeline
Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedDec 2013
Enrollment StartJan 2014
Primary CompletionFeb 2016
TodayJul 2026
First PostedDec 10, 2013
Enrollment StartJan 3, 2014
Primary CompletionFeb 22, 2016
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 12.6 years ago
Interventions
vildagliptin and metformin (combination)drug
vildagliptin and metformin combination therapy as 50mg/850mg bid or 50mg/1000mg bid
glimepiridedrug
Metformindrug